

業績サマリー（2020 年～）

論文業績

1. Strickler JH, Raimbourg J, Cohen JE, Ghiringhelli F, Sharma MR, Kitagawa C, Lee KH, O'Neil B, de Miguel M, Saada-Bouazid E, Li R, Rudra-Ganguly N, Luo A, Parikh A, Morrison-Thiele G, Neagu Aristide M, Hunter Z, Burns M, Kuboki Y. elisotuzumab Adizutecan (ABBV-400), a Novel c-Met-Targeting Antibody-Drug Conjugate: First-in-Human Results in Advanced Gastric/Gastroesophageal Junction Cancer. Clin Cancer Res. 2026.
2. Yoshida J, Fukuda N, Ito T, Nakano K, Kitagawa C, Mitani H, Takahashi S, Miura Y. Real-world platinum selection in immune checkpoint inhibitor-based therapy for recurrent or metastatic head and neck cancer: an exploratory multi-institutional retrospective study. Sci Rep. 2026.
3. Nishimura M, Kogawa T, Sugiyama K, Ozaki Y, Tanabe Y, Funasaka C, Kurozumi S, Yoshimura A, Iwasa T, Sakai H, Morita M, Watanabe S, Fujii T, Yamamoto M, Tsuji Y, Terada M, Ota T, Tokunaga S, Shimokawa M, Takano T. Abemaciclib rechallenge after progression on abemaciclib plus endocrine therapy in patients with hormone receptor-positive HER2-negative metastatic breast cancer: results from the phase II again study (WJOG14220B). Breast Cancer Research and Treatment. 2026.
4. Yosuke Kito 1, Kentaro Yamazaki 2, Hirokazu Shoji 3, Takeshi Yamada 4, Takahiro Tsushima 2, Seiichiro Mitani 5, Kazuhiro Shiraishi 6, Hisateru Yasui 7, Hiroki Hara 8, Kenro Hirata 9, Taito Esaki 10, Yudai Shinohara 11, Takao Tsuzuki 12, Shinya Kajiura 13, Toshiki Masuishi 14, Naoki Izawa 15, Eishi Baba 16, Kohei Murata 17, Naoya Akazawa 18, Yozo Suzuki 19, Hironaga Satake 20, Narikazu Boku 21, Ichinosuke Hyodo 22, Kenichi Yoshimura 23, Hisato Kawakami 24, Shuichi Hironaka 25, Kei Muro 14. Randomized phase II study of FOLFIRI plus ramucirumab versus FOLFOXIRI plus ramucirumab as first-line treatment for metastatic colorectal cancer: WJOG9216G (RECAST). Eur J Cancer. 2026.
5. Hitomi Sakai 1, Rika Kusumoto-Matsuo 2, Mari Hosonaga 3, Kazuki Nozawa 4, Manabu Futamura 5, Yuko Tanabe 6, Toru Mukohara 7, Kazuhiro Shiraishi 8, Tatsuya Toyama 9, Hiroyuki Yasojima 10, Noriyuki Watanabe 11, Hideki Sakai 12, Tsutomu Iwasa 13, Nobumichi Takeuchi 14, Hiroshi Tada 15, Kazuko Sakai 16, Natsuko Chiba 17, Toshimi Takano 3, Junji Tsurutani 2. BRCA1/2 Reversion Mutations in Japanese Patients with Metastatic Breast Cancer Progressing on Olaparib: OLIVE (WJOG15321B). Breast Cancer. 2026.
6. Yu Sunakawa 1, Hisateru Yasui 2, Manabu Shiozawa 3, Hiroyuki Takeda 4, Naoya Akazawa 5, Tamotsu Sagawa 6, Kazuhiro Shiraishi 7, Takahisa Kyogoku 8, Takashi Mine 9, Yasuhiro Yuasa 10, Takanori Watanabe 11 12, Tatsuya Kinjo 13, Yoshihiro Okita 14, Hiroyuki Okuyama 14, Satoshi Yuki 15, Koki Miyakawa 16, Ayana Kobara 16, Shoko Yanaka 17,

- Yukiko Abe 17, Wataru Ichikawa 18, Masashi Fujii 19, Akihito Tsuji 1. Plasma Biomarkers Associated with Clinical Outcomes of FOLFIRI Plus Ramucirumab in RAS Wild-Type Metastatic Colorectal Cancer: The JACCRO CC-16AR Trial. *Target Oncology*. 2026.
7. K. Sugiyama, Chau I. Sex-Based Survival Differences in Patients with Untreated Advanced Oesophageal Squamous Cell Carcinoma Receiving Chemotherapy and Immune Checkpoint Inhibitors: A Meta-Analysis. *ESMO Gastrointestinal Oncology*. 2026.
 8. K. Kato · K. Sugiyama · T. Ito · M. Yaguchi · S. Owaki · M. Sato · R. Ino · K. Shiraishi · Y. Uno · M. Hattori · M. Suenaga · M. Murayama · M. Shimada · Y. Kodera · C. Kitagawa. Improvement of survival in advanced gastric cancer over 15 years: real-world analysis by 5-year periods. *ESMO Gastrointestinal Oncology*. 2026.
 9. Sugiyama K, Ito T, Yaguchi M, Owaki S, Ino R, Sato M, Shiraishi K, Kato K, Imaizumi Y, Hino N, Murayama M, Shimada M, Uno Y, Hattori M, Suenaga M, Kodera Y, Kanda M, Kitagawa C. Nutritional Support for Treatment Continuity and Survival in Advanced Gastric Cancer: A Propensity Score-matched Study. *in vivo*. 2026.
 10. Ito T, Kato K, Yaguchi M, Owaki S, Sato M, Ino R, Shiraishi K, Sugiyama K, Uno Y, Hattori M, Suenaga M, Murayama M, Shimada M, Kodera Y, Kitagawa C. Clinical Outcomes in Advanced Gastric Cancer Among Patients Aged ≥ 80 Years Treated With Chemotherapy. *Anticancer Res*. 2026.
 11. Baba K, Suzuki N, Imamura CK, Booka E, Takeuchi M, Takahari D, Kawakami T, Kawakubo H, Kitagawa C, Kono Y, Ogura K, Kito Y, Saito K, Yamamoto S, Takeuchi H, Kudo T, Tsunoda T, Mizukami T, Yamaguchi T, Shoji H, Saito K, Tanoue K, Baba E, Nagashima K, Boku N. A phase I/II trial evaluating the safety of increased-dose S- 1 with oxaliplatin and nivolumab in HER2-negative advanced gastric cancer. *BMC Cancer*. 2025.
 12. Kikawa Y, Uemura Y, Taira T, Kitagawa C, Maeda H, Kato H, Hashimoto N, Hosoda M, Hamanaka Y, Tanabe Y, Yoshida T, Tane K, Takabatake D, Ishikawa T, Iwamoto T, Yamaguchi T, Takiguchi D, Mukai H, Taira N, Sangai T. Electronic Patient-Reported Outcomes With Vital Sign Monitoring During Trastuzumab Deruxtecan Therapy: The PRO-DUCE Randomized Clinical Trial. *JAMA Netw Open*. 2025.
 13. Sakai H, Tsurutani J, Ozaki Y, Ishiguro H, Nozawa K, Yamanaka T, Aogi K, Matsumoto K, Iwasa T, Tokiwa M, Tsuneizumi M, Miyoshi Y, Kitagawa C, Yamamoto M, Takano Y, Imamura CK, Chiba Y, Takiguchi D, Ezumi T, Takano T. Olanzapine for nausea and vomiting in people with breast cancer treated with trastuzumab deruxtecan: plain language summary of the ERICA study. *Future Oncol.*. 2025.
 14. P. Ntellas, A. Athauda, K. Sugiyama, M.L. Le, V. Crespi, I. Chau. Expanding the potential of antibody–drug conjugates in gastrointestinal malignancies: beyond HER2 targets. *ESMO Gastrointestinal Oncology*. 2025.
 15. Kodama H, Narita Y, Nakamura M, Takahashi M, Mizukami T, Ando T, Mitani S, Komori A, Hosokawa A, Moriwaki T, Sugiyama K, Taguri M, Orihara S, Kagamu H, Yamaguchi T,

- Nishikawa H, Muro K. A multicenter, prospective, observational study of nivolumab readministration for advanced gastric cancer (NIVO RETURNS). *Future Oncol.* 2025.
16. Sugiyama K, Kumar S, Chaudry A, Patel Nikhil, Patel Pranav, Cunningham D, Starling N, Rao S, Fribbens S, Chau I. Impact of Perioperative Fluorouracil, Leucovorin, Oxaliplatin, and Docetaxel Delivery on Postoperative Survival in Locally Advanced Oesophagogastric Adenocarcinoma. *Gastric Cancer.* 2025.
 17. Sugiyama K, Kumar S, Chaudry A, Patel Nikhil, Patel Pranav, Cunningham D, Starling N, Rao S, Fribbens S, Lucy E, Chau I. Impact of nutritional status on pathological response and recurrence-free survival in locally advanced oesophagogastric adenocarcinoma treated with perioperative FLOT therapy. *ESMO Gastrointestinal Oncology.* 2025.
 18. Sugiyama K, Starling N, Chau I. New Horizons with Growth Differentiation Factor 15 in Oncology: From Cancer Cachexia and Tumour Immunity to Novel Therapeutic Strategies. *Curr. Oncol.* 2025.
 19. Aoyama, T., Ooki, A., Oba, K. et al. A multicenter randomized open-label phase 2 study investigating optimal antiemetic therapy for patients with advanced/recurrent gastric cancer treated with trastuzumab deruxtecan: the EN-hance study. *Int J Clin Oncol.* 2025.
 20. Kazuhiro Shiraishi, Mao Okada, Shun Yamamoto, Yuki Matsubara, Toshiki Masuishi, Keitaro Shimozaaki, Yoshiyuki Yamamoto, Suguru Hirose, Keiji Sugiyama, Mitsuhiro Furuta, Nozomu Machida, Naoki Takahashi, Takako Yoshii, Yosuke Kito, Takao Tsuzuki, Shogen Boku, Kenji Tsuchihashi, Akinori Sugaya, Toshizo Takayama, Azusa Komori, Seiichiro Mitani, Toshihiko Matsumoto, Takashi Nishimura, and Kenro Hirata. The Efficacy and Safety of FOLFOX Therapy for Advanced Esophageal Squamous Cell Carcinoma. *Scientific reports.* 15. 2025.
 21. Sugiyama K, Chau I. Claudins as diagnostic tools and therapeutic targets-Glimpse of the horizon. *Cancer Treat Rev.* 133. 2025.
 22. Sugiyama K, Gordon A, Popat S, Okines A, Larkin J, Chau I. Is pathological response an adequate surrogate marker for survival in neoadjuvant therapy with immune checkpoint inhibitors?. *ESMO Open.* 10. 2025.
 23. Jumpei Yoshida, Keiji Sugiyama, Seira Owaki, Takumi Ito, Yuhei Yamaguchi, Ryosuke Emi, Yuki Sako, Mariko Satoh, Riku Ino, Kyoko Kato, Kazuhiro Shiraishi, Masaaki Shimada, Hiroyoshi Hattori, Chiyoe Kitagawa. Case Report: Efficacy of Combined Dabrafenib and Trametinib Therapy in BRAF V600E Mutant Intrahepatic Cholangiocarcinoma with a Neurofibromatosis Type 2 Mutation. *Intern Med.* 2025.
 24. Sugiyama K, Owaki S, Sato M, Shiraishi K, Kato K, Kitagawa C. Immunotherapy for Unresectable Small Bowel Adenocarcinoma: A Case Series. *in vivo.* 38. 2024.
 25. Kikuchi E, Hayakawa N, Nakayama M, Uno M, Nakatsu H, Kitagawa C, Miyake H, Yamada T, Fujita K, Shimoyama H, Nishihara K, Kobayashi M, Nakamura M, Fujimoto K, Sano T, Nishiyama N, Ito T, Kajita M, Kobayashi T, Kitamura H. J-AVENUE: A retrospective, real-world study evaluating patient characteristics and outcomes in patients with advanced

- urothelial carcinoma treated with avelumab first-line maintenance therapy in Japan. *Int J Urol*. 2024.
26. Masuda T, Miura S, Sato Y, Tachihara M, Bessho A, Nakamura A, Miyawaki T, Yoshimine K, Mori M, Shiraishi H, Hamai K, Haratani K, Maeda S, Tabata E, Kitagawa C, Tanizaki J, Imai T, Nogami S, Yamamoto N, Nakagawa K, Hattori N. Significance of micro-EGFR T790M mutations on EGFR-tyrosine kinase inhibitor efficacy in non-small cell lung cancer. *Sci Rep*. 13. 2023.
27. Izawa N, Masuishi T, Takahashi N, Shoji H, Yamamoto Y, Matsumoto T, Sugiyama K, Kajiwarra T, Kawakami K, Aomatsu N, Kondoh C, Kawakami H, Takegawa N, Esaki T, Shimokawa M, Nishio K, Narita Y, Hara H, Sunakawa Y, Boku N, Moriwaki T, Nakajima TE, Muro K. A Phase II Trial of Trifluridine/Tipiracil in Combination with Cetuximab Rechallenge in Patients with RAS Wild-Type mCRC Refractory to Prior Anti-EGFR Antibodies: WJOG8916G Trial. *Target Oncol*. 18. 2023.
28. Naoki Niikura 1, Takashi Yamanaka 2, Hironori Nomura 3, Kazuhiro Shiraishi 4, Hiroki Kusama 5, Mitsugu Yamamoto 6, Kazuo Matsuura 7, Kenichi Inoue 8, Sachiko Takahara 9, Shosuke Kita 10, Miki Yamaguchi 11, Tomoyuki Aruga 12, Nobuhiro Shibata 13, Akihiko Shimomura 14, Yuri Ozaki 15, Shuji Sakai 16, Yoko Kiga 17, Tadahiro Izutani 17, Kazuhito Shiosakai 18, Junji Tsurutani 19. Treatment with trastuzumab deruxtecan in patients with HER2-positive breast cancer and brain metastases and/or leptomeningeal disease (ROSET-BM). *NPJ Breast Cancer* .. 9. 2023.
29. H Yasui 1, Y Okita 2, M Nakamura 3, T Sagawa 4, T Watanabe 5, K Kataoka 6, D Manaka 7, K Shiraishi 8, N Akazawa 9, T Okuno 10, T Shimura 11, M Shiozawa 12, Y Sunakawa 13, H Ota 14, M Kotaka 15, H Okuyama 2, M Takeuchi 16, W Ichikawa 17, M Fujii 18, A Tsuji 19. Ramucirumab plus FOLFIRI as second-line treatment for patients with RAS wild-type metastatic colorectal cancer previously treated with anti-EGFR antibody: JACCRO CC-16. *ESMO Open*.. 8. 2023.
30. Sugiyama K. Perspective and Usage of the Clinical Guideline of Oncology from the Viewpoint of a Medical Oncologist Working at a Community Hospital. *Gan To Kagaku Ryoho*. 50. 148-150. 2023.
31. Sugiyama K, Shiraishi K, Motohashi T, Onoda S, Sato M, Kato K, Uda H, Hattori M, Suenaga M, Hirashima N, Shimada M, Kataoka M, Kitagawa C. The Impact of Nutritional Support on Survival Outcomes in Patients with Advanced Gastric Adenocarcinoma Treated with Chemotherapy. *Nutr Cancer*. 2023.
32. 白石和寛、杉山圭司、室圭. 腫瘍内科. 科学評論社. 29. 660-667. 2022.
33. Iwakoshi A, Sasaki E, Sato M, Sugiyama K, Kogure Y, Kitagawa C, Nishimura R. Thoracic SMARCA2-deficient But SMARCA4-preserved Tumors With Undifferentiated Morphology Combined With Claudin-4 Negativity. *Am J Surg Pathol*.. 2022.

34. Jumpei Yoshida, Keiji Sugiyama, Mariko Satoh, Kazuhiro Shiraishi, Riko Nishibori, Chiyoe Kitagawa. Efficacy of trastuzumab deruxtecan in an advanced gastric cancer patient with brain metastasis. Current Problems in Cancer. 100757. 2021.
35. Keiji Sugiyama, Ai Izumika, Akari Iwakoshi, Riko Nishibori, Mariko Sato, Kazuhiro Shiraishi, Hiroyoshi Hattori, Rieko Nishimura, Chiyoe Kitagawa. Successful Alectinib Treatment for Carcinoma of Unknown Primary with EML4-ALK Fusion Gene: A Case Report. Current Oncology. 28. 1938-1945. 2021.
36. Shigenori Kadowaki , Toshiki Masuishi, Takashi Ura, Keiji Sugiyama, Seiichiro Mitani , Yukiya Narita, Hiroya Taniguchi, and Kei Muro. A triplet combination of FOLFOXIRI plus cetuximab as first-line treatment in RAS wild-type, metastatic colorectal cancer: a dose-escalation phase Ib study. International Journal of Clinical Oncology. 26. 701-707. 2021.
37. Sugiyama K. Sarcopenia and Nutrition Support in the Treatment of Gastric Cancer. Gan To Kagaku Ryoho. 47. 1542-1546. 2020.
38. Sugiyama K, Shiraishi K, Sato M, Nishibori R, Nozawa K, Kitagawa C. Chemotherapy by FOLFIRI Regimen for Poorly Differentiated Gastrointestinal Neuroendocrine Carcinoma. J Gastrointest Cancer.. 2020.

学会発表

1. The effectiveness and safety of the second-line chemotherapy after nivolumab plus ipilimumab for advanced esophageal squamous cell carcinoma (ESMO-GI 2026、ミュンヘン、2026.7.4)
2. 成人発症、副鼻腔原発横紋筋肉腫に対するケースシリーズ (第 50 回日本頭頸部癌学会、東京、2026.6.12)
3. FOLFOX plus nivolumab for advanced esophageal squamous cell carcinoma in the elderly (第 80 回食道学会、福島、2026.6.25)
4. リフィーディング症候群を伴う巨大鼻腔原発扁平上皮癌に対し多職種連携で治療し得た 1 例 (第 259 回東海内科地方会、岐阜、2026.6.21)
5. 名古屋医療センターにおける進行胃癌薬物療法の変遷と担い手の変化 (第 98 回胃癌学会総会、沖縄、2026.03.05)
6. 化学療法中の進行胃癌患者における栄養サポートの生存への影響 (第 98 回胃癌学会総会、沖縄、2026.03.05)
7. 高齢進行胃癌患者 (80 歳以上) に対する化学療法の治療成績 (第 98 回胃癌学会総会、沖縄、2026.03.06)
8. 進行胃癌における生存成績の時代変化：15 年間の後方視的解析 (第 98 回胃癌学会総会、沖縄、2026.03.06)

9. Survival Benefit of Nutritional Support in Advanced Gastric Cancer Patients Receiving Chemotherapy: A Propensity Score-Matched Study (ASCO-GI2026、サンフランシスコ、2026.1.8)
10. Clinical outcomes in advanced gastric cancer among elderly patients (≥ 80 -year-old) treated with chemotherapy (ASCO-GI2026、サンフランシスコ、2026.1.8)
11. Efficacy of the Combined Chemotherapy and Pembrolizumab Therapy in POLE-mutated Dedifferentiated Endometrial Carcinoma: A case study (第 62 回癌治療学会、横浜、2025.10.18)
12. Sex-Based Survival Differences in Untreated Advanced Oesophageal Squamous Cell Carcinoma with Chemotherapy and Immune Checkpoint Inhibitors : A Meta-Analysis (第 63 回癌治療学会、横浜、2025.10.17)
13. A retrospective observational study to evaluate the efficacy of trifluridine/tipiracil $\pm$ bevacizumab in metastatic colorectal cancer with MSI-high/deficient MMR (第 63 回癌治療学会、横浜、2025.10.16)
14. Efficacy and Safety of Chemotherapy Plus Pembrolizumab for Early Triple-Negative Breast Cancer (第 22 回日本臨床腫瘍学会学術集会、神戸、2025.3.6)
15. Durvalumab Plus Tremelimumab for Advanced Hepatocellular Carcinoma with Contraindications to Anti-Angiogenic Agents (第 22 回日本臨床腫瘍学会学術集会、神戸、2025.3.6)
16. The impact of nutritional status on the pathological response and recurrence-free survival in LA-OGA treated with perioperative FLOT (ASCO-GI2025、サンフランシスコ、2025.01.23)
17. Is treatment delivery of perioperative FLOT therapy in locally advanced-OGA associated with recurrence-free survival? (ASCO-GI2025、サンフランシスコ、2025.01.23)
18. Impact of age and single heterozygous UGT1A1 on the safety and efficacy of first-line FOLFIRI or FOLFOXIRI in combination with ramucirumab (RAM) for metastatic colorectal cancer (mCRC): subgroup analyses of WJOG9216G (RECAST) (ESMO2024、バルセロナ、2024.9.16)
19. Final analysis of the JACCRO CC-16: Ramucirumab plus FOLFIRI for RAS wild-type mCRC refractory to anti-EGFR antibody (ESMO2024、2024.9.12)
20. R0 切除後早期に肝転移を認めた胃神経内分泌癌の 2 例 (第 96 回日本胃癌学会総会、京都、2024.2.28-3.1)
21. JSMO SNS 元年 (第 21 回日本臨床腫瘍学会学術集会、名古屋、2024.2.22-24)
22. A prospective observational study of MSI screening in chemotherapy-naïve advanced gastric cancer: WJOG13320GPS (第 21 回日本臨床腫瘍学会学術集会、名古屋、2024.02.22-24)

23. Biweekly versus weekly paclitaxel for early breast cancer: A retrospective, single-center study (第 31 回日本乳癌学会学術総会、横浜、2023.06)
24. 切除不能食道扁平上皮癌における FOLFOX 療法に関する多施設後ろ向き観察研究 (食道学会、大阪、2023.6)
25. Randomized phase II study of FOLFIRI plus ramucirumab versus FOLFOXIRI plus ramucirumab as first-line treatment for patients with metastatic colorectal cancer: WJOG9216G (RECAST) (第 20 回日本臨床腫瘍学会学術集会、福岡、2023.03)
26. 高齢者切除不能・再発胃癌に対する S-1 単剤療法と S-1/L-OHP 併用 (SOX) 療法のランダム化第 II 相試験 (第 20 回日本臨床腫瘍学会学術集会、福岡、2023.03)
27. BRAFV600E 変異型切除不能進行・再発大腸癌に対する FOLFOXIRI+/-Bevacizumab 療法と Doublet 療法の有効性および安全性に関する後方視的検討 (第 20 回日本臨床腫瘍学会学術集会、福岡、2023.03)
28. A multicenter phase II study of mFOLFOX6 in advanced gastric cancer patients with severe peritoneal metastases (第 20 回日本臨床腫瘍学会学術集会、福岡、2023.03)
29. First-line FOLFOX for advanced esophageal squamous cell carcinoma: a multi-institutional retrospective study (第 20 回日本臨床腫瘍学会学術集会、福岡、2023.03)
30. A randomized phase II study comparing S-1 plus oxaliplatin with S-1 monotherapy for elderly patients with advanced gastric cancer: WJOG8315G (第 20 回日本臨床腫瘍学会学術集会、福岡、2023.03)
31. Multicenter retrospective study of vulnerable patients with metastatic colorectal cancer: results of first-line therapy (第 20 回日本臨床腫瘍学会学術集会、福岡、2023.03)
32. Treatment outcomes of chemotherapy for gastric cancer with early recurrence (第 20 回日本臨床腫瘍学会学術集会、福岡、2023.03)
33. FOLFOX + ニボルマブ療法後に Conversion surgery を実施した進行胃腺癌の 2 例 (第 95 回胃癌学会、札幌、2023.2)
34. 食欲、体重の先に何がある？がん悪液質治療の意義を考える (第 95 回胃癌学会、札幌、2023.2)
35. A multicenter phase II study of mFOLFOX6 in advanced gastric cancer patients with severe peritoneal metastases (第 95 回胃癌学会、札幌、2023.2)
36. Plasma biomarkers to predict clinical outcomes of FOLFIRI plus ramucirumab (RAM) as 2nd-line treatment for RAS wild-type metastatic colorectal cancer: JACCRO CC-16AR (ASCO-GI 2023、サンフランシスコ、2023.01)
37. Vulnerable patients with metastatic colorectal cancer in a real-world setting: a multicenter retrospective study (ASCO-GI 2023、サンフランシスコ、2023.01)

38. Late line FOLFOX therapy after prior cisplatin-based regimen in advanced esophageal squamous cell carcinoma: a multi-institutional retrospective study (ESMO-ASIA2022、シンガポール、2022/12/2-12/4)
39. Treatment with trastuzumab deruxtecan in patients with HER2-positive breast cancer and brain metastases and/or leptomeningeal disease: A retrospective chart review study (SABCS、サンアントニオ、2022.12)
40. FOLFOX-based palliative chemoradiotherapy for metastatic or advanced esophageal squamous cell carcinoma: multi-institute retrospective study (第 60 回癌治療学会学術集会、神戸、2022.10.22)
41. FOLFOX-based definitive chemoradiotherapy for esophageal squamous cell carcinoma: (第 60 回癌治療学会学術集会、神戸、2022.10.22)
42. A multicenter phase II study of mFOLFOX6 in advanced gastric cancer patients with severe peritoneal metastases: WJOG10517G (ESMO-GI、パリ、2022/9/9-9/13)
43. a multicenter retrospective study (第 94 回日本胃癌学会総会、web、2022/3/2-4)
44. The impact of nutrition support and Glasgow prognostic score in advanced gastric cancer patients treated by chemotherapy (第 19 回日本臨床腫瘍学会学術集会、京都、2022/2/17-19)
45. FOLFOX-based chemoradiotherapy for locally advanced/metastatic esophageal squamous cell carcinoma with severe dysphagia (第 19 回日本臨床腫瘍学会学術集会、京都、2022/2/17-19)
46. A phase I study of FLOT as first-line treatment for advanced gastric cancer with or without severe peritoneal metastasis (第 19 回日本臨床腫瘍学会学術集会、京都、2022/2/17-19)
47. Single institute case review: first-line systemic therapy for HER2-positive metastatic breast cancer in pertuzumab era (第 19 回日本臨床腫瘍学会学術集会、京都、2022/2/17-19)
48. Treatment outcome and relapse of serious immune-related adverse events in patients with solid malignancies (第 19 回日本臨床腫瘍学会学術集会、京都、2022/2/17-19)
49. Efficacy of trastuzumab deruxtecan for HER2-positive breast and gastric cancer with brain metastases: two case reports (第 19 回日本臨床腫瘍学会学術集会、京都、2022/2/17-19)
50. A multicenter phase 2 trial of ramucirumab plus FOLFIRI as second-line treatment for patients with RAS wild-type metastatic colorectal cancer previously treated with combination chemotherapy with anti-EGFR antibody: JACCRO CC-16 (ASCO GI 2022、web、2022/1/20-22)
51. A phase I study of FLOT as first-line treatment for advanced gastric cancer with/without severe peritoneal metastasis: dose finding (ASCO GI 2022、web、2022/1/20-22)

52. A phase I study of FLOT as a first-line therapy for Japanese patients with advanced gastric cancer including patients with/without severe peritoneal metastasis (ESMO 2021、web、2021/5/30-6/3)
53. FOLFOX or FOLFOX plus radiation therapy for locally advanced or metastatic esophageal squamous cell carcinoma (第 18 回日本臨床腫瘍学会学術集会、京都、2021/2/18-20)
54. Chemoradiation with carboplatin plus paclitaxel for esophageal squamous cell carcinoma patients with severe renal dysfunction or synchronous lung cancer (第 18 回日本臨床腫瘍学会学術集会、京都、2021/2/18-20)
55. 高齢者乳がんにおける周術期化学療法の安全性と忍容性の検討 (第 28 回日本乳癌学会学術総会、web、2020/10/13-15)
56. 局所進行・遠隔転移(limited metastasis)を有する胃癌に対する導入 FLOT 療法 (第 58 回癌治療学会、京都、2020.10.22)
57. 消化器神経内分泌癌に対する FOLFIRI 療法 (第 58 回癌治療学会、京都、2020.10.22)
58. 非ホジキンリンパ腫と再発胆嚢癌合併例に対して細胞傷害性抗がん剤、分子標的薬治療を行った 1 例 (第 82 回日本血液学会、京都、2020/10/10-11/8)
59. 高度肝障害を有する切除不能 HER2 陽性乳がんに対して抗 HER2 療法が奏効した一例 (第 17 回乳癌中部地方会、web、2020/9/12-13)